Results 211 to 220 of about 335,332 (300)

Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Comorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden. Methods We included individuals with ≥ 2 MG diagnoses
Sari Atula, Fredrik Piehl, Ingrid Schager, Fredrik Berggren, Karin Humle, Mari Savolainen, Didier Pitsi, Juha Mehtälä, Aino Vesikansa, Riina‐Minna Väänänen, Tero Ylisaukko‐oja, John Vissing   +11 more
wiley   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

The predictive value of dyslipidemia for immune reconstitution outcome among HIV/AIDS patients after 24 months of viral suppression: a retrospective cohort study. [PDF]

BMC Infect Dis
Jin Y, Chen Q, Xia T, Gai Y.
europepmc   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

2025 Egyptian guidelines for the management of dyslipidemia. [PDF]

Egypt Heart J
Reda A, Taha HS, Badran HM, Khamis H, Kamal S, Elserafy AS, Dawoud MH, Elamragy AA, Bendary A, Shaker MM.   +9 more
europepmc   +1 more source

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

Obesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

A serial 4-year cross-sectional study of dyslipidemia on Pamirs Plateau, the roof of the world. [PDF]

BMC Med
Liu Y, Shu Y, Wang X, Li B, Su D, Huangfu C, Huang Z, Wang Y, Zhang S, Wang T, Gao C, Luo L, Ren Z, Wang R, Gao Y, Zhou W.   +15 more
europepmc   +1 more source

Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide approval in 2021 in the United States.
Olajide A. Adekunle, Phuc Le, Christopher Boyer, Hamlet Gasoyan, Dev Yash Gupta, Ha T. Tran, Yihua Yue, Michael B. Rothberg   +7 more
wiley   +1 more source

Obesity as a predictor of atherogenic dyslipidemia in patients with metabolic dysfunction associated steatotic liver disease. [PDF]

Sci Rep
Fotros D, Hekmatdoost A, Yari Z.
europepmc   +1 more source

Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models

Obesity, EarlyView.
ABSTRACT Objective/Methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP‐1 receptor agonist retatrutide in diet‐induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
François Briand, Camille Le Cudennec, Estelle Grasset, Natalia Breyner, Claire Bigot, Pierre Dillard, Thierry Sulpice   +6 more
wiley   +1 more source